Adlai Nortye, a Phase 3 biotech developing immunotherapies for various cancers, submitted a blank filing on Tuesday, after setting terms last month to raise $72 million by offering 3 million ADSs at a price range of $22 to $26. In its latest filing, the company also removed CITIC CLSA as an underwriter, leaving Cantor Fitzgerald as sole bookrunner, and disclosed financials for the six months ended June 30, 2023.
Operating through subsidiaries in the US and China, Adlai Nortye focused on developing innovative cancer therapies for patients across the spectrum of tumor types. The company's pipeline contains six drug candidates, three of which are clinical-stage. Its lead candidate, AN2025, is a pan-phosphoinositide 3-kinase inhibitor that is designed to act against solid tumors. In-licensed from Novartis, AN2025 is currently undergoing a Phase 3 trial for recurrent or metastatic head and neck squamous cell carcinomas after disease progression with anti-PD-1/PD-L1 therapy. The company expects to enroll 483 patients in more than 180 sites across 18 jurisdictions, covering North America, Europe, Asia, and South America. Adlai Nortye expects to submit an NDA to the FDA seeking potential accelerated approval in the 2H24.
The Cayman Islands-based company was founded in 2004 and plans to list on the Nasdaq under the symbol ANL. Cantor Fitzgerald is the sole bookrunner on the deal.
